A pilot study of low-dose erythromycin in bronchiectasis

Patients with bronchiectasis suffer from sputum production, recurrent exacerbations, and progressive airway destruction. Erythromycin is effective in diffuse panbronchiolitis, another suppurative airway disorder, although its efficacy is unknown in idiopathic bronchiectasis. A double-blind placebo-controlled study was therefore conducted to evaluate the effects of 8-week administration of low dose erythromycin (500 mg b.i.d.) in steady-state idiopathic bronchiectasis. Patients in the erythromycin group (n=11, 8 female, mean age 50+/-15 yrs), but not the placebo group (n=10, 8 female, mean age 59+/-16 yrs) had significantly improved forced expiratory volume in one second, forced vital capacity and 24-h sputum volume after 8 weeks (p<0.05). There was no parallel improvement in sputum pathogens, leukocytes, interleukin (IL)-1alpha and IL-8, tumour necrosis factor-alpha, or leukotriene B4. The results of this pilot study show that low-dose erythromycin improves lung function and sputum volume in bronchiectasis. Further studies are indicated to evaluate the efficacy of long-term erythromycin therapy in bronchiectasis.

This article has been cited by other articles:

				M. P. Murray, J. L. Pentland, and A. T. Hill A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis Eur. Respir. J., November 1, 2009; 34(5): 1086 - 1092. [Abstract] [Full Text] [PDF]

				M. P. Murray, K. Turnbull, S. MacQuarrie, and A. T. Hill Assessing response to treatment of exacerbations of bronchiectasis in adults Eur. Respir. J., February 1, 2009; 33(2): 312 - 318. [Abstract] [Full Text] [PDF]

				P. A. J. Crosbie and M. A. Woodhead Long-term macrolide therapy in chronic inflammatory airway diseases Eur. Respir. J., January 1, 2009; 33(1): 171 - 181. [Abstract] [Full Text] [PDF]

				A. E. O'Donnell Bronchiectasis Chest, October 1, 2008; 134(4): 815 - 823. [Abstract] [Full Text] [PDF]

				D. E. Stover and D. Mangino Macrolides: A Treatment Alternative for Bronchiolitis Obliterans Organizing Pneumonia? Chest, November 1, 2005; 128(5): 3611 - 3617. [Abstract] [Full Text] [PDF]

				S C Bell, S L Senini, and J G McCormack Macrolides in cystic fibrosis Chronic Respiratory Disease, April 1, 2005; 2(2): 85 - 98. [Abstract] [PDF]

				P. Scheinberg, E. Shore, and on behalf of the PC-TNDS-008 Study Group A Pilot Study of the Safety and Efficacy of Tobramycin Solution for Inhalation in Patients With Severe Bronchiectasis Chest, April 1, 2005; 127(4): 1420 - 1426. [Abstract] [Full Text] [PDF]

				K W Tsang, K C Tan, P L Ho, G C Ooi, J C Ho, J Mak, G L Tipoe, C Ko, C Yan, W K Lam, et al. Inhaled fluticasone in bronchiectasis: a 12 month study Thorax, March 1, 2005; 60(3): 239 - 243. [Abstract] [Full Text] [PDF]

				G. W. Amsden Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J. Antimicrob. Chemother., January 1, 2005; 55(1): 10 - 21. [Abstract] [Full Text] [PDF]

				G Davies and R Wilson Prophylactic antibiotic treatment of bronchiectasis with azithromycin Thorax, June 1, 2004; 59(6): 540 - 541. [Full Text] [PDF]

				K.W. Tsang, P. Ng, P.L. Ho, S. Chan, G. Tipoe, R. Leung, J. Sun, J.C. Ho, M.S. Ip, and W.K. Lam Effects of erythromycin on Pseudomonas aeruginosa adherence to collagen and morphology in vitro Eur. Respir. J., March 1, 2003; 21(3): 401 - 406. [Abstract] [Full Text] [PDF]

				K. W. Garey, A. Alwani, L. H. Danziger, and I. Rubinstein Tissue Reparative Effects of Macrolide Antibiotics in Chronic Inflammatory Sinopulmonary Diseases Chest, January 1, 2003; 123(1): 261 - 265. [Abstract] [Full Text] [PDF]

				A. F. Barker Bronchiectasis N. Engl. J. Med., May 2, 2002; 346(18): 1383 - 1393. [Full Text] [PDF]

				M. Gorrini, A. Lupi, S. Viglio, F. Pamparana, G. Cetta, P. Iadarola, J. C. Powers, and M. Luisetti Inhibition of Human Neutrophil Elastase by Erythromycin and Flurythromycin, Two Macrolide Antibiotics Am. J. Respir. Cell Mol. Biol., October 1, 2001; 25(4): 492 - 499. [Abstract] [Full Text] [PDF]

				A. F. BARKER, L. COUCH, S. B. FIEL, M. H. GOTFRIED, J. ILOWITE, K. C. MEYER, A. O'DONNELL, S. A. SAHN, L. J. SMITH, J. O. STEWART, et al. Tobramycin Solution for Inhalation Reduces Sputum Pseudomonas aeruginosa Density in Bronchiectasis Am. J. Respir. Crit. Care Med., August 1, 2000; 162(2): 481 - 485. [Abstract] [Full Text] [PDF]

				K. W. Tsang, K.-n. Chan, P.-l. Ho, L. Zheng, G. C. Ooi, J. C. M. Ho, and W.-k. Lam Sputum Elastase in Steady-State Bronchiectasis Chest, February 1, 2000; 117(2): 420 - 426. [Abstract] [Full Text] [PDF]